Small Pharma Inc. (DMTTF) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en London, United Kingdom. El CEO actual es George Tziras.
DMTTF tiene fecha de IPO 2021-06-07, cotiza en el Other OTC, una capitalización de mercado de $37.51M.
Small Pharma Inc., a biotechnology company, focuses on developing short-acting psychedelics with therapy for the treatment of mental health conditions. Its clinical program is N,N-dimethyltryptamine assisted therapy to treat major depressive disorder. The company's product includes SPL026 Placebo, which is in clinical Phase IIA for the treatment of major depressive disorder. Its preclinical stage programs include SPL028, a prolonged DMT series; SPL029, an oral DMT series; and SPL801 oral formulation of 6-hydroxynorketamin. The company was incorporated in 2015 and is headquartered in London, the United Kingdom.
